All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-09-07T08:16:43.000Z

Update on triplet therapy with ivosidenib, venetoclax, and azacitidine

By Erika Roa, Kreena Mistry
Featured
Curtis Lachowiez
Sep 7, 2022
Share:

Bookmark this article

During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked for an update on triplet therapy with ivosidenib, venetoclax, and azacitidine.

Update on triplet therapy with ivosidenib, venetoclax, and azacitidine.

In this video, Lachowiez discusses an updated analysis of the completed phase Ib portion of the study of ivosidenib combined with venetoclax, either with/without azacitidine, presented at ASCO 2022. Lachowiez outlines the study design and enrollment criteria, then goes on to discuss adverse effects and response rates for the different patient groups. Finally, Lachowiez describes findings on IDH-1 clearance rates, overall survival, MRD, and the upcoming phase II expansion cohorts.

More about...
AML-related mutationsASCO 2022AzacitidineIvosidenibVenetoclax

Related articles

Add bookmark

2022 ELN recommendations for the management of AML in adults

A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.

Sep 28, 2022
Add bookmark

2022 ELN recommendations for the management of AML in adults

A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.

Sep 28, 2022
Add bookmark

Treatment of older or unfit patients with AML

Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.

Nov 27, 2019
Add bookmark

Treatment of older or unfit patients with AML

Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st...

Nov 27, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox